Carvedilol update iv: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure

Drugs of Today

Volumn 33, Issue 7, 1997, Pages 453-473

  Feuerstein, Giora Z ^a   Shusterman, Neil H ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ANTIOXIDANT ACTIVITY; APOPTOSIS; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; HEART PROTECTION; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; NEUTROPHIL CHEMOTAXIS; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; REVIEW; VASODILATATION; VERTIGO; VISUAL IMPAIRMENT;

EID: 0030868061     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1997.33.7.442004     Document Type: Review

References (93)

1. McKee, P.A., Castelli, W.P., McNamara, P.M., Kannel, W.B. The natural history of congestive heart failure: The Framingham study. New Engl J Med 1971, 285: 1441-6.
2. Sutton, G.C.S. Epidemiological aspects of heart failure. Am Heart J 1990, 120: 1538-40.
3. Schocken, D.D., Arrieta, M.I., Laverton, P.E., Ross, E.A. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992, 20: 301-6.
4. Wheeldon, N.M., MacDonald, T.M., Flucker, C.J., McKendrick, A.D., McDevitt, D.C., Struthers, A.D. Echocardiography in chronic heart failure in the community. Q J Med 1993, 86: 17-23.
5. McMurray, J., McDonagh, T., Morrison, C.E., Dargie, H.J. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993, 14: 1158-62.
6. Ho, K.K., Pinsky, J.L., Kannel, W.B., Levy, D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993, 22(4, Suppl. A): 6-13A.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987, 316: 1429-35.
8. Pfeffer, M.A., Braunwald, E., Moye, L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. New Engl J Med 1992, 327: 669-77.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 1991, 325: 293-302.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1992, 327: 685-91.
11. Leimbach, W.N., Jr., Wallin, B.G., Victor, R.G., Aylward, P.E., Sundlof, G., Mark, A.L. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986, 73: 913-9.
12. Cohn, J.N., Levine, B., Olivari, T.M. et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med 1984, 311: 819-23.
13. Francis, G.S., Benedict, C., Johnstone, D.E. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990, 82: 1724-70.
14. Krum, H., Gu, A., Wilshire-Clement, M. et al. Changes in plasma levels of endothelin reflect the long term clinical and hemodynamic effects of beta-blockade in patients with chronic heart failure. J Am Coll Cardiol 1994, 172A.
15. Clavell, A., Stingo, A., Margulies, K., Lerman, A., Underwood, D., Burunett, J.C. Physiological significance of endothelin: Its role in congestive heart failure. Circulation 1993, 87: V45-50.
16. Pitt, B., Segal, R., Martinez, F.A. et al. Randomized trial of losartan versus captopril in patients over 65 with heart failre (Evaluation of Losartain in the Elderly Study, ELITE). Lancet 1977, 349: 747-52.
17. Waagstein, R., Hjalmarson, A., Varnauskas, E., Wallentin, I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975, 37: 1022-36.
18. Waagstein, F., Bristow, R.M., Swedeberg, K. et al. Beneficial effects of metaprolol in idiopathic dilated cardiomyopathy. Lancet 1993, 342: 1441-6.
19. CIBIS. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994, 90: 1765-73.
20. Nichols, A.J., Sulpizio, A.C., Ashton, D.J., Hieble, J.P., Ruffolo, R.R. Jr. In vitro pharmacologic profile of the novel β-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989, 39: 327-36.
21. 1-radrenoceptors. Chirality 1989, 1: 265-70.
22. Nichols, A.J., Gellai, M., Ruffolo, R.R. Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent. Fundam Clin Pharmacol 1991, 5: 25-38.
23. 2-adrenoceptor subtypes: Therapeutic implications. Exp Opin Invest Drugs 1997, 6(4): 367-87.
24. Smith, E.F., Sliviak, M.J., Gagnon, R. Single and repeated doses of the vasodilator/β-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat. Cardiovasc Drugs Ther 1992, 6: 499-504.
25. Willette, R.N., Sauerrnelch, C.F., Ruffolo, R.R. Jr. Local cutaneous hemodynamic effects of carvedilol and labetalol in the anesthetized rat. Eur J Pharmacol 1990, 176: 237-40.
26. Gellai, M., DeWolf, R., Ruffolo, R.R. Jr. Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats. Pharmacology 1990, 41: 200-6.
27. Ruffolo, R.R., Boyle, D.A., Brooks, D.P. et al. Carvedilol: A novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 1992, 10(2): 127-57.
28. Podrid, P.J., Fogel, R.I., Tordjman-Fuchs, T. Arrhythmia in patients with cardiomyopathy and congestive heart failure. In: Congestive Heart Failure. Hosenpund, J.D., Greenberg, B.A. (Eds.). Springer Verlag: New York 1994, 645-86.
29. Bril, A., Tomasi, V., Laville, M.P. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to regional ischemia and reperfusion. Pharmacol Commun 1995, 5: 291-300.
30. Brunvand, H., Froyland, L., Hexeberg, E., Rynning, S.E., Berge, R.K., Grong, K. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur J Pharmacol 1996, 314: 99-107.
31. Brunvand, H., Kvitting, P., Rynning, S.E., Berge, R.K., Grong, K. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. J Cardiovasc Pharmacol 1996, 28: 409-17.
32. Yue, T-L., Cheng, H.Y., Lysko, P.G. et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992, 263(1): 92-8.
33. Yue, T-L., Liu, T., Feuerstein, G. Carvedilol: A new vasodilator and β-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992, 1(1): 27-35.
34. Yue, T-L., McKenna, P.J., Gu, J.L., Cheng, H.Y., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993, 22: 922-8.
35. Yue, T-L., Wang, X., Gu, J-L., Ruffolo, R.R. Jr., Feuerstein, G. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995, 273(3): 1442-9.
36. Yue, T-L., McKenna, P.J., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvedilol, a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992, 214: 277-80.
37. Feuerstein, R., Yue, T.L. Carvedilol: A novel multiple action antihypertensive drug that provides major organ protection. Cardiovasc Drug Rev 1994, 12(2): 85-104.
38. Yue, T-L., McKenna, P.J., Lysko, P.G. et al. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994, 251: 237-43.
39. Yue, T-L., McKenna, P.J., Gu, J.L., Cheng, H.Y., Ruffolo, R.R. Jr., Feuerstein, G.Z. Carvediloi, a new vasodilating β-adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiol Res 1994, 28: 400-6.
40. Lysko, P.G., Lysko, K.A., Yue, T-L., Webb, C.L., Gu, J-L., Feuerstein, G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 1992, 23: 1630-6.
41. Lysko, P.G., Feuerstein, G.Z., Ruffolo, R.R. Jr. Carvedilol: A novel multiple action antihypertensive drug (Technical Review). Pharm News 1995, 2(3): 12-6.
42. Christopher, T.A., Yue, T-L., Feuerstein, G.Z., Ruffolo, R.R. Jr., Lopez, B.L., Ma, X-L. Carvedilol, a new β-adrenoreceptor blocker, vasodilator and free radical scavenger, exerts an anti-shock and endothelial protective effect in rat splanchnic ischemia and reperfusion. J Pharmacol Exp Ther 1995, 273: 64-71.
43. Lopez, B.L., Christopher, T.A., Yue, T-L., Feuerstein, G.Z., Ma, X-L., Ruffolo, R.R. Jr. Carvedilol, a new β-adrenoceptor blocker antihypertensive drug, protects against free radical-induced endothelial dysfunction. Pharmacology 1995, 51: 165-73.
44. Ma, X.L., Lopez, B.L., Liu, G-L. et al. Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 1997, 80: 894-901.
45. Maggi, E., Marchesi, E., Covini, D., Negro, C., Perani, G., Bellomo, G. Protective effect of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996, 27: 532-8.
46. Kramer, J.H., Weglicki, W.B. A hydroxylated analog of the β-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radic Biol Med 1996, 21: 813-25.
47. Engler, R.L., Dahlgren, M.D., Morris, D.D., Peterson, M.A., Schmid-Schonbein, G.W. Role of leukocytes in the response to acute myocardial ischemia and reflow in dogs. Am J Physiol 1986, 251: H314-23.
48. Go, L.O., Murray, C.E., Richard, V.J., Weischedel, G.R., Jennings, R.B., Reimer, K.A. Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury. Am J Physiol 1988, 255: H1188-98.
49. Smith, E.F., Griswold, D.E., Egan, J.W., Hillegass, L.M., DiMartino, M.J. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist, BM 13.505. J Cardiovasc Pharmacol 1989, 13: 715-22.
50. Bril, A., Slivjak, M., DiMartino, J. et al. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: Comparison with propranolol. Cardiovasc Res 1992, 26: 518-25.
51. Ma, X-L., Yue, T-L., Lopez, B.L. et al. Carvedilol, a new β-adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996, 277(1): 128-36.
52. Ruffolo, R.R., Boyle, D.A., Brooks, D.P. et al. Carvedilol: A novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 1992, 10(2): 127-57.
53. Ruffolo, R.R., Boyle, D.A., Venuti, R.P., Lukas, M.A. Preclinical and clinical pharmacology of carvedilol. J Human Hypertens 1993, 7(1): S2-15.
54. Feuerstein, G.Z., Poste, G., Ruffolo, R.R. Carvedilol update III: Rationale for use in congestive heart failure. Drugs Today 1995, 31: 307-26.
55. Feuerstein, G.Z., Ruffolo, R.R. Jr. Comparison of the ability of two vasodilating β-blockers, carvedilol and celiprolol to reduce infarct size in a pig model of acute myocardial infarction. Pharmacol Commun 1994, 5: 57-63.
56. Christopher, T., Lopez, B., Feuerstein, G., Ruffolo, R.R. Jr., Ma, X-L., Yue, T-L. A hydroxylated metabolite of the β-adrenoceptor antagonist, carvedilol, attenuates post-ischemic splanchnic tissue injury. Am J Physiol, in press.
57. Hamburger, S.A., Barone, F.C., Feuerstein, G.Z., Ruffolo, R.R. Jr. Carvedilol (Kredex®) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991, 43: 113-20.
58. Feuerstein, G.Z., Yue, T-L., Ruffolo, R.R. Jr., Ma, X-L. Comparison of carvedilol and metoprolol cardioprotective drugs. J Cardiovasc Pharmacol, in preparation.
59. DiPette, D.J., Frohlich, E.D. Cardiac involvement in hypertension. Am J Cardiol 1988, 61: 40-6.
60. Hansson, L., Svensson, A., Dalhof, B., Eggertsen, R. Drug treatment of hypertension. Handbook Hypertens 1992, 15: 655-708.
61. Ohlstein, E.H., Vickery, L., Arleth, A. et al. Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 1994, 16: 163-77.
62. Barone, F.C., Nelson, A.M., Ohlstein, E.H. et al. Chronic carvedilol and propranolol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 1996, 279: 948-55.
63. Barone, F.C., Campbell, W.G., Nelson, A.H., Feuerstein, G.Z. Carvedilol prevents severe hypertension induced cardiomyopathy and remodeling. J Hypertens 1997, in review.
64. Kerr, J.F.R., Wyllie, A.H., Currie, A.R. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1992, 26: 239-57.
65. Narula, J., Haider, N., Virmani, R. et al. Apoptosis in myocytes in end stage heart failure. New Engl J Med 1996, 335: 1182-9.
66. Mallat, L., Tedgui, A., Fontaliran, F., Frank, R., Durigon, M., Fontain, G. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. New Engl J Med 1996, 334: 1190-6.
67. Feuerstein, G., Ruffolo, R.R. Jr., Yue, T-L. Apoptosis and heart failure. Trends Cardiovasc Med 1997, in press.
68. Yue, T-L., Ma, X-L., Romanic, A.M. et al. Involvement of stress activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion induced myocyte apoptosis by carvedilol. Circ Res 1997, in press.
69. Reed, J.C. Double identity for proteins of Bcl-2 family. Science 1997, 387: 773-6.
70. Force, T., Pombo, C.M., Arruch, J.A., Bonventre, J.V., Kyriakis, J.M. Stress activated protein kinase in cardiovascular diseases. Circ Res 1996, 78: 947-53.
71. Schreck, R., Reiber, P., Baeccerle, P.A. Reactive oxygen intermediates as apparently widely used second messengers in the activation of NF-אB transcription factor and HIV-1. EMBO J 1991, 10: 2247-58.
72. 1-adrenergic response. J Clin Invest 1983, 72: 732-8.
73. Dupont, A.G., Vander-Nieran, P., Tallymaloney, Y. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987, Suppl. 11: 5130-6.
74. Krum, H.G., Wilshire-Clement, M., Miller, M., Medina, N., Yushak, M., Packer, M. Changes in plasma levels of endothelin reflect the long term clinical and hemodynamic effects of beta-blockade in patients with chronic heart failure. J Am Coll Cardiol 1994, 172A.
75. Ohlstein, E.H., Arleth, A.J., Storer, B., Romanic, A.M. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cell. J Mol Cell Cardiol 1997, in review.
76. Ohlstein, E.H., Douglas, S.A., Sung, C-P. et al. Carvedilol, a novel cardiovascular drug prevents vascular smooth muscle proliferation, migration and neointima formation following vascular injury. Proc Natl Acad Sci 1993, 90: 6189-93.
77. Krown, K.A., Page, M.T., Nguyen, C. et al. Tumor necrosis factor-α induced apoptosis in cardiac myocytes. J Clin Invest 1996, 98: 2854-65.
78. Lomas, B., Gill, E.A., Rodrigez-Larrain, J., Abraham, W.T., Bristow, M.R., Gilbert, E.M. Carvedilol is associated with a reversal of remodeling in chronic heart failure. Circulation 1996, 94: 1407.
79. Why, H.J.F., Richardson, P.J. Effect of carvedilol on left ventricle function and mass in hypertension. J Cardiovasc Pharmacol 1992, 19(Suppl. 1): 550-4.
80. Doughty, R.N., Whalley, G.A., Gamble, G., MacMahon, S., Sharpe, N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997, 29: 1060-6.
81. Australian-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995, 92: 212-8.
82. Olsen, S.L., Gilbert, E.M., Renlund, D.G., Taylor, D.O., Yanowitz, F.D., Bristow, M.R. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 1995, 25: 1225-31.
83. Krum, H., Sackner-Bernstein, J.D., Goldsmith, R.L. et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995, 92: 1499-506.
84. Metra, M., Nardi, M., Giubbini, R., Cas, L.D. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1678-87.
85. Packer, M., Bristow, M.R., Conn, J.N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996: 334: 1349-55.
86. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995, 92: 212-8.
87. Australial-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997, 349: 375-80.
88. Bristow, M.R., Gilbert, E.M., Abraham, W.T. et al. for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94: 2807-16.
89. Packer, M., Colucci, W.S., Sackner-Bernstein, J. et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure; The PRECISE trial. Circulation 1996, 94: 2793-9.
90. Colucci, W.S., Packer, M., Bristow, M.R. et al. for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996, 94: 2800-6.
91. Cohn, J.N., Fowler, M.B., Bristow, M.A. et al. Effect of carvedilol in severe chronic heart failure. J Am Coll Cardiol 1996, 27(Suppl. A): Abst 169A.
92. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1992, 327: 685-91.
93. Feldman, A.M., Bristow, M.R., Parmley, W.W. et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. New Engl J Med 1993, 329: 149-55.